Rankings
▼
Calendar
INDV Q3 2025 Earnings — Indivior Pharmaceuticals Inc Revenue & Financial Results | Market Cap Arena
INDV
Indivior Pharmaceuticals Inc
$4B
Q3 2025 Earnings
Healthcare
Drug Manufacturers - Specialty & Generic
Income Statement
Revenue
$314M
+2.3% YoY
Gross Profit
$230M
73.2% margin
Operating Income
$43M
13.7% margin
Net Income
$42M
13.4% margin
EPS (Diluted)
$0.33
QoQ Revenue Growth
+4.0%
Cash Flow
Operating Cash Flow
-$39M
Free Cash Flow
-$59M
Stock-Based Comp.
$7M
Balance Sheet
Total Assets
$1.4B
Total Liabilities
$1.6B
Stockholders' Equity
-$207M
Cash & Equivalents
$445M
Year-over-Year Comparison
Metric
Current
Year Ago
Change
Revenue
$314M
$307M
+2.3%
Gross Profit
$230M
$238M
-3.4%
Operating Income
$43M
$4M
+975.0%
Net Income
$42M
$4M
+950.0%
Revenue Segments
Reportable Segment
$314M
100%
← FY 2025
All Quarters
Q4 2025 →